| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Chimmitecan targets the enzyme topoisomerase I. It stabilizes the topoisomerase I-DNA covalent complex, a transient intermediate formed during DNA replication. By stabilizing this complex, chimmitecan prevents the re-ligation of the DNA strand, leading to the accumulation of DNA single-strand breaks. During DNA replication, these breaks are converted into lethal double-strand breaks, which ultimately trigger apoptosis in rapidly dividing cancer cells. This mechanism of action is characteristic of the camptothecin class of anticancer agents.
|
|---|---|
| ln Vitro |
In vitro, chimmitecan demonstrates potent antiproliferative activity against a wide range of cancer cell lines. It has shown remarkable effectiveness against cancers characterized by rapid cell division, such as colorectal and ovarian cancers. The compound's activity is attributed to its potent inhibition of topoisomerase I and the subsequent induction of DNA damage and apoptosis. Chimmitecan displays outstanding in vitro activity, and its substitution at the 9-position is believed to confer a salient anti-multidrug resistance (MDR) activity.
|
| ln Vivo |
In vivo, chimmitecan has demonstrated strong anticancer activity in preclinical studies. It has shown broad-spectrum antitumor effects in various animal models, including models of drug-resistant and solid tumors. Chimmitecan offers improved stability and pharmacokinetic properties compared to traditional camptothecins, making it a promising candidate for oncology research. Its in vivo efficacy is a result of its potent topoisomerase I inhibition and the subsequent induction of apoptosis in tumor cells.
|
| Enzyme Assay |
Topoisomerase I inhibition assays are performed using purified topoisomerase I enzyme and a DNA substrate, such as supercoiled plasmid DNA. The enzyme's ability to relax supercoiled DNA is measured by agarose gel electrophoresis. Chimmitecan is tested at various concentrations, and the concentration required to inhibit 50% of the enzyme's activity (IC50) is calculated. The compound's ability to stabilize the topoisomerase I-DNA covalent complex can also be assessed using specific assays that trap the cleavable complex.
|
| Cell Assay |
In vitro cellular assays are performed using various cancer cell lines, such as colorectal (e.g., HCT116), ovarian (e.g., A2780), and other solid tumor cell lines. Cells are cultured in appropriate media at 37°C in a 5% CO₂ incubator. Chimmitecan, dissolved in DMSO, is added to the culture medium at various concentrations. After incubation for 48-72 hours, cell viability is assessed using standard assays like MTT or CellTiter-Glo to determine IC50 values. Apoptosis is evaluated by Annexin V staining or caspase activity assays. DNA damage is assessed by measuring γH2AX foci formation or by Comet assay.
|
| Animal Protocol |
In vivo efficacy is evaluated in murine xenograft models using human cancer cell lines, including drug-resistant and solid tumor models. Chimmitecan is administered via various routes, such as intravenous, intraperitoneal, or oral, depending on the study design. Tumor growth is monitored by caliper measurements. Endpoints include tumor volume, tumor weight, survival, and histopathological analysis of tumors to assess apoptosis and proliferation. Pharmacokinetic studies are conducted to determine plasma concentrations, half-life, and bioavailability.
|
| ADME/Pharmacokinetics |
Chimmitecan has a molecular weight of 404.42 g/mol and a molecular formula of C23H20N2O5. Its CAS number is 185425-25-6. The compound has a LogP of 2.513, indicating moderate lipophilicity. It is typically stored as a powder at -20°C for up to 3 years or at 4°C for 2 years. It is soluble in DMSO. Chimmitecan is a synthetic camptothecin analog that offers improved stability and pharmacokinetic properties compared to traditional camptothecins.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for chimmitecan are not extensively documented in the available literature. However, as a topoisomerase I inhibitor, its toxicity profile is expected to be similar to that of other camptothecin analogs. Common toxicities associated with this class of drugs include myelosuppression (particularly neutropenia and thrombocytopenia), gastrointestinal effects (nausea, vomiting, diarrhea), and alopecia. The compound's improved pharmacokinetic properties may allow for better tolerability. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only and not for human therapeutic applications.
|
| Additional Infomation |
Chimmitecan is a potent topoisomerase I inhibitor and a synthetic camptothecin analog. It has demonstrated strong anticancer activity in preclinical studies, with broad-spectrum antitumor effects, including activity against drug-resistant and solid tumor models. Chimmitecan offers improved stability and pharmacokinetic properties compared to traditional camptothecins, making it a promising candidate in oncology research. It is used to investigate mechanisms of DNA damage response and to evaluate novel therapeutic strategies. Chimmitecan is an active metabolite of simmitecan and is available from various suppliers for research purposes only.
|
| Molecular Formula |
C23H20N2O5
|
|---|---|
| Molecular Weight |
404.4153
|
| Exact Mass |
404.137
|
| CAS # |
185425-25-6
|
| PubChem CID |
11603813
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.513
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
864
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([C@](C([H])([H])C([H])([H])[H])(C2C([H])=C3C4C(=C([H])C5C(C([H])([H])C([H])=C([H])[H])=C(C([H])=C([H])C=5N=4)O[H])C([H])([H])N3C(C=2C1([H])[H])=O)O[H])=O
|
| InChi Key |
AXXPNDLHTNUMIK-QHCPKHFHSA-N
|
| InChi Code |
InChI=1S/C23H20N2O5/c1-3-5-13-14-8-12-10-25-18(20(12)24-17(14)6-7-19(13)26)9-16-15(21(25)27)11-30-22(28)23(16,29)4-2/h3,6-9,26,29H,1,4-5,10-11H2,2H3/t23-/m0/s1
|
| Chemical Name |
(19S)-19-ethyl-7,19-dihydroxy-8-prop-2-enyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4727 mL | 12.3634 mL | 24.7268 mL | |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL | |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
